EMD Serono and MD Anderson enter three-year collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, and MD Anderson Cancer Center announced a three-year strategic collaboration, with the aim of more quickly advancing the development of investigational cancer therapies in four cancers–breast, colorectal, glioblastoma and leukemia.

EMD Serono will be the first company to gain access to the Adaptive Patient-Oriented Longitudinal Learning and Optimization Platform (APOLLO)—MD Anderson’s research platform that standardizes the long-term collection of patients’ medical history and data derived from tissue samples to better understand the biology of cancer and accelerate research-driven patient care.

The collaboration will encompass both biomarker-focused pre-clinical research and clinical trials in specific tumor types aimed at identifying biomarkers of response and resistance and developing a better understanding of the disease biology.

The collaboration will enhance the value of EMD Serono’s future oncology/immuno-oncology pipeline, with a goal of multiple registrational studies in novel indications in the next two to three years. Data from APOLLO will be used to match a number of investigational compounds to select tumor types for potential development and collaboratively design biomarker-driven pre-clinical and clinical studies at MD Anderson evaluating the potential therapeutic effect of the compounds—alone or in combination.

APOLLO was developed by MD Anderson as part of its Moon Shots Program, an ambitious effort to reduce cancer deaths by more rapidly developing and implementing advances in prevention, early detection and treatment based on scientific discoveries.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login